Organic Active Ingredients TRIZ Cases

Compound (I) monosodium salt overcomes incomplete NLRP3 inhibition by existing therapies, providing complete protection and rapid symptom relief.

siRNAs degrade angiotensinogen mRNA, avoiding RAAS compensatory mechanisms that limit conventional inhibitors.

Sulfur-free lignosulfonate compositions delay diabetes onset and reduce antibiotic reliance by converting pathogen reproduction into a controlled process.

Segmented atomoxetine dosage forms deliver rapid onset and sustained therapeutic levels.

Copper halide catalysts replace toxic mutagens in thiazolyl-pyrazolo[1,5-a]pyrimidine synthesis to boost yield.

Macrocyclic compounds inhibit PDE1B to treat neurodegenerative disorders where current therapies lack efficacy.

Volatile solvents evaporate from adhesive formulations to form solidified peelable layers that maintain sustained drug delivery on stretching skin.

Adjusting inner water phase osmotic pressure to 2-8 times the outer phase stabilizes liposomes and prevents drug leakage during storage.

Crystalline solid forms of a toll-like receptor 8 modulator deliver targeted therapeutic benefit while minimizing off-target liabilities.

Natural lichen compounds replace toxic synthetic agents to provide safe depigmenting activity without regulatory restrictions.

Substituted 2-benzylidene-2H-benzo[b][1,4]thiazin-3(4H)-ones selectively inhibit CK2, CDK9, and PIM1 kinases to block cancer cell proliferation.

Selective receptor blockade resolves the trade-off between therapeutic efficacy and adverse side effects like weight gain.

Crystalline nanoparticle formulations with surfactants improve pharmacokinetic properties and brain penetration of mixed lineage kinase inhibitors.

Specific pyrazole structures inhibit myeloma cell proliferation, addressing the lack of effective low molecular weight therapeutic agents.

Stacking rearing trays utilizes vertical space for insect breeding.

Biodegradable haptic reservoirs deliver active agents directly to the eye through controlled polymer degradation.

Adjusting aqueous lipid formulation pH to 2-5.5 suppresses ester bond hydrolysis, extending pharmaceutical shelf-life without cryoprotectants.

Formula I opioids modulate peripheral receptors for pain relief while avoiding central side effects by excluding brain penetration.

Optimized indazole structures enhance FGFR inhibition potency while reducing toxicity and side effects associated with high-dose conventional inhibitors.

BA-1049 (R) enantiomer selectively targets ROCK2 to promote neural repair.

Low APEX1 and APEX2 with high MPG predict glioma sensitivity to DNA-damaging agents by disrupting Base Excision Repair.

Peptide conjugates selectively deliver maytansinoid derivatives to acidic tumor environments, reducing peripheral neuropathy from systemic toxicity.

Ionizable lipid particles encapsulate messenger RNA to resolve nuclease degradation in the bloodstream while enabling sustained protein expression.

A chemical composition accelerates stem cell differentiation into insulin-producing cells using putrescine, glucosamine, and nicotinamide.

Modular benzothiazole scaffolds resolve synthesis complexity while delivering high affinity binding to the histamine H3 receptor.

Concomitant APC-targeted immunosuppressants condition immune tolerance to viral transfer vectors.

Combining omega-3 fatty acids with sleep-inducing agents creates a therapeutic composition.

Novel heterocyclic compounds act as negative allosteric modulators targeting the mGlu5 receptor to inhibit the micturition reflex.

Benzimidazole derivatives inhibit ITK and TRKA kinases, suppressing T cell-driven inflammation and pruritus in atopic dermatitis.

A cyclopropene complex maintains high substance levels through controlled molecular encapsulation.

Genetic testing determines fAIM exon 3 copy counts to identify cats predisposed to tubulointerstitial fibrosis and enable early preventive intervention.

A transdermal therapeutic system delivers guanfacine using a mono-carboxylic acid permeation enhancer.

Stable crystalline macrolide forms enable targeted anti-inflammatory treatment without antibiotic resistance risks.

Ammonium thienopyrimidine derivatives inhibit anti-apoptotic Bcl-2 proteins, overcoming chemoresistance by enhancing solubility and pro-apoptotic activity.

Segmenting C5 into distinct epitopes allows non-competing antibody combinations that reduce red blood cell lysis.

Small molecule compounds inhibit IL-17A with oral bioavailability, avoiding immunogenicity and infection risks associated with biological antagonists.

Micronising asenapine maleate at low temperature and pressure yields a stable monoclinic form with controlled particle size.

Nitazoxanide protects hepatocytes from ammonia-induced toxicity, improving liver detoxification and synthesis functions in acute liver failure.

Modified phthalazinone structures balance therapeutic efficacy and safety profiles for treating PARP-mediated diseases.

Crystalline salts of IRAK4 inhibitor Compound I resolve efficacy and specificity limitations in treating inflammatory disorders.

Copper-catalyzed coupling builds the core structure, and stereochemical control establishes the active R-enantiomer to resolve low yield and poor specificity.

Preconditioning agents protect ependymal cells during intrathecal oncolytic virus administration.

Continuous spin freeze-drying rotates vials to create uniform frozen layers, resolving batch variability and enhancing nucleic acid stability.